Ipca Laboratories has informed that it enclosed the media release issued by the Company with respect to launch of patented novel drug branded as ‘Diulcus’ in the Indian market for treatment of Diabetic Foot Ulcer (DFU). Currently there is a global unmet medical need for treatment of DFU which is the most prevalent complication caused by chronic diabetes.
The above information is a part of company’s filings submitted to BSE.